Name

mini-BEAM

Alternate names

BEAM

Primary Site

None

Histology

None

Radiation

None

Remarks

None

Drugs for mini-BEAM

Name

Alternate Names

Dom-Etoposide
Epipodophyllotoxin derivative
Epipodophyllotoxin ethylidene gluco-pyranoside
Eposine
Ethylidene-Lignan P
Etopophos
Podophyllotoxin derivative
Vepesid
VP 16-213
VP-16
VP-16213
Toposar

Abbreviations

EPEG
VP-16
VP-16-213

Category

Chemotherapy

Subcategory

Epipodophyllotoxin, topoisomerase II inhibitor
Plant alkaloid

NSC Number

141540

Primary Site

Gastric cancer
Hodgkins lymphoma
Lung cancer (NSCLC, SCLC)
Non-Hodgkin lymphoma
testicular cancer (Germ cell tumors)

Histology

None

Remarks

Plant alkaloid. FDA approved use on small-cell lung cancer, testicular cancer.

Coding

This drug should be coded

Name

Alternate Names

Alanine mustard
Alkeran
CB-3025
DL Sarcolysine
DL-O-Sarcolysin
L-Phenylalanine Mustard
L-Sarcolysin
Melfalan
Phenylalanine Mustard
Sarcolysine
Sarkoklorin
Sarkolizin
WR-19813

Abbreviations

L-PAM
MPL
PAM

Category

Chemotherapy

Subcategory

Alkylating agent

NSC Number

8806
008806
57199

Primary Site

Multiple myeloma
ovarian cancer
Polycythemia Vera

Histology

None

Remarks

Alkylating antineoplastic agent. FDA approved uses on multiple myeloma and epithelial non-resectable ovarian carcinoma.
Also used in the high-dose chemotherapy and transplant setting.
Mechanism of action: Analog of nitrogen mustard

Coding

This drug should be coded

Name

Alternate Names

AC-1075
Alexan
Ara-cytidine
Arabinocytidine
Arabinosylcytosine
Beta-Arabinosylcytosine
Cytarabin
Cytarabine
Cytarabinoside
Cytosar
Cytosar-U
Cytosine Arabinoside
Cytosine arabinoside hydrochloride
Spongocytidine HCL
Tarabine
Tarabine PFS
U-19920
U-19920A
WR-28453

Abbreviations

ara-C
CA
HDA
HDARA-C

Category

Chemotherapy

Subcategory

Antimetabolite

NSC Number

063878
63878

Primary Site

ALL
AML
CML
head and neck
Hodgkin's disease
leukemia
Meningeal leukemia
NHL

Histology

None

Remarks

Antineoplastic agent; antimetabolite. FDA approved uses on Hodgkin's disease, leukemia; under investigation for Rx of Progressive Multifocal Leukoencephalopathy (PML)

Coding

This drug should be coded

Name

Alternate Names

BiCNU
Carmustinea
DTI 015
DTI-015
DTI015
WR 139021
WR-139021
WR139021

Abbreviations

BCNU

Category

Chemotherapy

Subcategory

Alkylating agent

NSC Number

409962

Primary Site

Brain
Hodgkin Lymphoma
Kidney cancer
Multiple myeloma
Non-Hodgkin lymphoma

Histology

None

Remarks

Phase I FDA approved uses on brain tumor, Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma. Guilford Pharmaceuticals.(nitrosourea) (alkylating agent)

Coding

This drug should be coded
Glossary